All In Biotech

NDA 201923 · Alimera Sciences INC

Iluvien

Fluocinolone Acetonide · Intravitreal · Corticosteroid

Priority review

Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Sep 26, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

63

20 Phase 3, 7 recruiting

FAERS reports

2,447

1,130 serious, 51 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 28, 2026.

ILUVIEN is a corticosteroid indicated for: the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. (1.1) the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. (1.2) 1.1 Diabetic Macular Edema ILUVIEN ® is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. 1.2 Chronic Non-Infectious Uveitis Affecting the Posterior Segment ILUVIEN ® is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Mechanism: Corticosteroids inhibit inflammatory responses to a variety of inciting agents including multiple inflammatory cytokines. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. Corticosteroids are thought to act by inhibition of phospholipase A 2 via induction of inhibitory proteins collectively called lipocortins. It is postulated that these proteins control biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 26, 2014 Original approval · Type 3 - New Dosage Form · priority review LabelReviewLetter
1 products under this application
  • ILUVIEN · FLUOCINOLONE ACETONIDE 0.19MG · IMPLANT, INTRAVITREAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluocinolone Acetonide" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective197
  • intraocular pressure increased192
  • off label use169
  • pruritus166
  • rash144
  • diarrhoea115
  • device failure111
  • psoriasis95
  • device dislocation92
  • headache90
  • fatigue89
  • circumstance or information capable of leading to medication error87

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200514
20067
200711
20089
200915
201017
201128
201232
201317
201426
201554
201684
201795
2018103
2019267
2020159
2021193
2022248
2023225
2024277
2025356
2026202

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Iluvien (Fluocinolone Acetonide) · HCPCS J7313

2024 spending

$8.9M

Beneficiaries

792

909 claims

Per beneficiary

$11,219

2024 ASP limit $490.64 per unit

View as table
YearSpending
2020$10,211,072
2021$9,494,400
2022$10,877,018
2023$10,538,920
2024$8,885,136

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 140 on PubMed

Sponsor: Alimera Sciences INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.